Jun 24 |
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
|
Jun 20 |
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
|
Jun 17 |
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
|
Jun 3 |
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
|
May 29 |
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
|
May 28 |
Enlivex Therapeutics announces up to $15M registered direct offering
|
May 28 |
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
|
May 21 |
We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate
|
Apr 29 |
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
Apr 29 |
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
|